Menkes' disease: long-term treatment with copper and D-penicillamine

Area of Science:

• Genetics
• Biochemistry
• Pediatrics

Background:

• Menkes' disease is a rare X-linked recessive disorder affecting copper metabolism.
• It leads to neurodegeneration and early mortality due to impaired copper-dependent enzyme activity.
• Current copper treatments have not significantly altered the disease's progression.

Observation:

• A case study of an 8.5-year-old boy with an unusually mild form of Menkes' disease is presented.
• The patient received alternating intramuscular copper-histidine and oral D-penicillamine treatment.
• Compared to an untreated maternal uncle, the patient exhibited normal growth and intellectual development, despite ataxia and speech issues.

Findings:

• Parenteral copper-histidine combined with oral D-penicillamine therapy resulted in a markedly milder disease phenotype.
• This treatment approach preserved normal growth and intellectual development in the patient.
• The patient still experienced some neurological symptoms, including ataxia and speech difficulties.

Implications:

• This combined therapeutic strategy may offer significant benefits for early-treated Menkes' disease patients.
• It suggests a potential new avenue for managing this severe inherited copper metabolism disorder.
• Further research is warranted to validate the efficacy and long-term outcomes of this treatment regimen.